To investigate the prognostic value of elevated C-reactive protein levels in patients with stable angina who underwent coronary stenting.
We followed a consecutive series of 1152 patients with stable angina who had undergone coronary stenting. We measured baseline C-reactive protein levels before stenting with a high-sensitivity assay; 651 patients (57%) had elevated C-reactive protein levels (>5 mg/L). The primary endpoint was either death or myocardial infarction within 1 year after the procedure. Angiographic restenosis was defined as a ≥50% diameter stenosis at follow-up angiography.
During the 1-year follow-up, 62 (9.5%) of the 651 patients with an elevated C-reactive protein level and 24 (4.8%) of the 501 patients with normal levels died or had a myocardial infarction (P = 0.002). In a multivariate analysis, elevated baseline C-reactive protein levels were associated with almost a twofold increase in the rate of death or myocardial infarction after coronary stenting (hazard ratio = 1.8; 95% confidence interval: 1.1 to 2.9). Most of the difference in the event rates developed within the first 30 days. Baseline C-reactive protein levels did not correlate with restenosis.
Elevated preprocedural C-reactive protein levels are associated with a less favorable prognosis in patients with stable angina who undergo coronary stenting. The measurement of C-reactive protein levels in these patients may help to identify those who may benefit from a treatment strategy aimed at the attenuation of inflammation.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of Medicine
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.N Engl J Med. 1997; 336: 973-979
- Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project.Arterioscler Thromb Vasc Biol. 1997; 17: 1121-1127
- C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes.J Am Coll Cardiol. 1998; 31: 1460-1465
- C-reactive protein as a cardiovascular risk factor.Circulation. 1999; 100: 96-102
- C-reactive protein in healthy and in sick populations.Eur Heart J. 2000; 21: 1564-1565
- The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina.N Engl J Med. 1994; 331: 417-424
- Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty.J Am Coll Cardiol. 1999; 34: 1512-1521
- Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation.J Am Coll Cardiol. 2001; 37: 839-846
- Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention.Circulation. 2001; 104: 992-997
- Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients.Circulation. 2002; 105: 1412-1415
- The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty.Eur Heart J. 2002; 23: 960-966
- A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents.N Engl J Med. 1996; 334: 1084-1089
- Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease.Circulation. 1990; 82: 1193-1202
- Stable ischemic syndromes.in: Topol E.J. Textbook of Cardiovascular Medicine. 3rd ed. Lippincott-Raven, Philadelphia, Pennsylvania1998: 333-364
- Chronic ischemic heart disease.in: Braunwald E. Heart Disease A Textbook of Cardiovascular Medicine. 3rd ed. W. B. Saunders Company, Philadelphia, Pennsylvania1988: 1314-1378
- Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.Lancet. 1998; 352: 87-92
- Intracoronary stenting and risk for major adverse cardiac events during the first month.Circulation. 1998; 98: 104-111
- Immunoradiometric assay of circulating C-reactive protein.Clin Chem. 2000; 46: 934-938
- What is C-reactive protein telling us about coronary artery disease?.Arch Intern Med. 2002; 162: 389-392
- Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation.J Am Coll Cardiol. 2001; 38: 2006-2012
- High-sensitivity C-reactive protein.Circulation. 2001; 103: 1813-1818
- C-reactive protein, inflammation, and innate immunity.Immunol Res. 2001; 24: 163-176
- C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor.Blood. 1993; 82: 513-520
- Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease.Circulation. 2000; 102: 1000-1006
- Direct proinflammatory effect of C-reactive protein on human endothelial cells.Circulation. 2000; 102: 2165-2168
- Need to test the arterial inflammation hypothesis.Circulation. 2002; 106: 136-140
- Effect of statin therapy on C-reactive protein levels.JAMA. 2001; 286: 64-70
- Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein.Am J Cardiol. 2001; 88: 672-674
- Effect of beta blockers on expression of interleukin-6 and C-reactive protein in patients with unstable angina pectoris.Am J Cardiol. 2001; 88: 422-424
- Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (Fenofibrate versus Atorvastatin Trial—FAT).Cardiovasc Res. 2001; 52: 290-298
- Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury.Circulation. 2001; 104: 2716-2721
- Short-term effects of atorvastatin on C-reactive protein.Eur Heart J. 2002; 23: 794-799
Accepted: February 3, 2003
Received: September 20, 2002
© 2003 Excerpta Medica Inc. Published by Elsevier Inc. All rights reserved.